NervGen Pharma Corp Closes Non-Brokered Private Placement finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NervGen Pharma Corp.: NervGen Pharma Grants Stock Options
Vancouver, British Columbia (Newsfile Corp. - July 16, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisable at $2.00 per share for a period of three years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company s stock option plan.
NervGen Pharma Corp : NervGen Engages Vorticom Inc to Provide Media Relations Services finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NervGen Pharma Corp.: NervGen Pharma Reports First Quarter 2021 Results
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. We achieved several key milestones in the first quarter of 2021 including receiving clearance from the FDA to proceed with our Phase 1 clinical trial for our lead compound, NVG-291, which has now commenced in Australia, stated Paul Brennan, NervGen s President & CEO. In addition, we established an Alzheimer s Disease Scientific Advisory Board comprised of world-class scientists and clinical researchers in Alzheimer s disease and have decided to initiate a multi-dose Alzheimer s disease patient cohort as a Phase 1b addition to our clinical program. We also received Orphan Designation for NVG-291 from the European Medicines Agenc